Observational studies and the withdrawal of rofecoxib.
Watson
Douglas J
DJ
Department of Epidemiology, Merck Research Laboratories, West Point, PA, USA. douglas_watson@merck.com
Santanello
Nancy C
NC
D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D003627:Data Interpretation, Statistical; D004348:Drug Labeling; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000139:chemically induced / Q000453:epidemiology; D019370:Observation; D017891:Pharmacoepidemiology; D011358:Product Surveillance, Postmarketing / Q000379:methods*; D018570:Risk Assessment; D013450:Sulfones / Q000009:adverse effects*; D013923:Thromboembolism / Q000139:chemically induced / Q000453:epidemiology
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib